Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 28, 2026
Can you apply?
This grant is for researchers and research institutions seeking funding to conduct clinical trials investigating alcohol treatment, pharmacotherapy approaches, and recovery outcomes. Eligible applicants typically include academic medical centers, universities, research hospitals, and nonprofit research organizations with institutional research infrastructure (IRB, regulatory compliance, clinical research capacity). Applicants must have qualified research personnel, access to study populations, and ability to conduct randomized controlled trials or other rigorous clinical trial designs. Small businesses may be eligible under some NIH mechanisms. Funding supports domestic U.S.-based research with focus on developing evidence-based pharmaceutical and behavioral interventions for alcohol use disorder treatment and recovery monitoring.
Not the right fit? Find grants for your organization in 5 questions →
Program description
The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Required documents
- SF-424 (R&R) Application for Federal Assistance
- Project Narrative (research strategy, typically 15 pages)
- Specific Aims (1 page)
- Research Design and Methods section detailing trial protocol
- Budget and Budget Justification (Form SF-424 R&R)
- Biographical Sketches (current CV format) for key personnel
- Letters of Support/Commitment from collaborating institutions
- Protection of Human Subjects documentation (IRB approval or exemption determination)
- Data Management and Sharing Plan
- Vertebrate Animals section (if applicable)
- Resource Sharing Plan
- Previous Research Support documentation
- Institutional environment and commitment letter
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.273 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$125,900,663
-
$34,675,742
-
$34,469,501
-
$33,261,336
-
$32,897,567
-
$31,652,514
-
$30,394,602
-
$29,223,384
-
$29,195,978
-
$29,168,993
Top States by Funding
- CA 16 awards $250.8M
- NY 3 awards $162.6M
- OR 7 awards $96.3M
- NC 4 awards $67.1M
- IN 3 awards $61.9M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.273). How funding has trended year over year.
| 2024 | $430,377,419 | |
| 2025 | $429,906,735 | |
| 2026 est. | $12,401,560 |
FAQ
What types of organizations can apply for this R01 grant?
Academic institutions, research hospitals, universities, nonprofit research organizations, and small businesses with research capabilities can apply. Your institution must have the infrastructure to conduct clinical trials, including IRB approval processes and regulatory compliance experience.
Is a clinical trial required?
Yes. The grant title explicitly requires a clinical trial component. This means you must propose a randomized controlled trial or other rigorous prospective clinical study design testing alcohol treatment or pharmacotherapy interventions.
What are typical funding amounts and duration?
NIH R01 grants typically fund $250,000-$500,000+ in direct costs annually for 3-5 years, though amounts vary by institute and research scope. Consult the specific RFP for exact funding levels.
What is the deadline and how long does review take?
The deadline is September 7, 2026. NIH peer review typically takes 4-6 months after submission, followed by council review.
What makes an application competitive?
Strong preliminary data, clear clinical relevance, rigorous trial design, qualified team (including biostatistician and clinical investigators), and alignment with NIH/NIAAA strategic priorities strengthen competitiveness. Novel pharmacological targets and diverse participant recruitment strengthen applications.
💡 Tips for applicants
- Establish strong preliminary data early: pilot studies or published data demonstrating feasibility of your intervention and ability to recruit/retain participants are critical for R01 competitiveness.
- Partner with experienced clinical trial coordinators and biostatisticians: NIH reviewers assess the team's capacity to manage complex trials; include letters of commitment from key personnel.
- Design rigorous, adequately powered trials: use gold-standard comparators or active controls rather than placebo when ethically appropriate; justify sample sizes with power analyses.
- Address diversity and inclusion: NIH now requires meaningful recruitment and retention of diverse populations. Specify recruitment strategies for underrepresented groups in alcohol treatment research.
- Align with NIAAA strategic priorities: review the National Institute on Alcohol Abuse and Alcoholism's strategic plan; highlight how your pharmacotherapy or treatment approach addresses priority research gaps.
⚠️ Common mistakes
Applications often fail due to weak preliminary data or insufficient evidence that the proposed intervention is ready for clinical testing. Reviewers frequently reject proposals with poorly designed trials (inadequate controls, underpowered, unclear primary outcomes). Poor team composition—missing biostatisticians, clinical trial coordinators, or subject-matter experts—significantly reduces competitiveness and raises concerns about feasibility.
Similar grants
- OPEN Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required) — National Institutes of Health
- OPEN Alcohol Health Services Research (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Alcohol Health Services Research (R34 Clinical Trial Optional) — National Institutes of Health
- OPEN Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) — National Institutes of Health